Alonso, Cristina

Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests

Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentMetabolomics and Mass Spectrometry Studies

Cited by 451

Metabolomic identification of subtypes of nonalcoholic steatohepatitis

Alonso, C., Fernández-Ramos, D., Varela-Rey, M., Martínez-Arranz, I., Navasa, N., Van Liempd, S. M., Lavín Trueba, J. L., Mayo, R., Ilisso, C. P., de Juan, V. G., et al. (2017) · Gastroenterology

Liver Disease Diagnosis and TreatmentMetabolomics and Mass Spectrometry Studies

Cited by 263

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., et al. (2024) · Nature Metabolism

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 262

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 214

Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD

Marques, V., Afonso, M. B., Bierig, N., Duarte-Ramos, F., Santos-Laso, Á., Jimenez-Agüero, R., Eizaguirre, E., Bujanda, L., Pareja, M. J., Luís, R., et al. (2021) · Frontiers in Medicine

Liver Disease Diagnosis and TreatmentAdipokines, Inflammation, and Metabolic Diseases

Cited by 69

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

Martínez‐Arranz, I., Bruzzone, C., Noureddin, M., Gil‐Redondo, R., Mincholé, I., Bizkarguenaga, M., Arretxe, E., Iruarrizaga‐Lejarreta, M., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 65

A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH

Fraser, D. A., Wang, X., Lund, J., Nikolić, N., Iruarrizaga-Lejarreta, M., Skjaeret, T., Alonso, C., Kastelein, J. J. P., Rustan, A. C., Kim, Y. O., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentFatty Acid Research and Health

Cited by 41